| Old Articles: <Older 5331-5340 Newer> |
|---|
 |
The Motley Fool
December 30, 2008
Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership.   |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
The Motley Fool
December 30, 2008
Brian Orelli |
The FDA Needs a Bake Sale Money seems to be at the root of the problem with the FDA right now. It's pretty clear that fees, even though they're up to over $1 million per marketing application, aren't enough to get things done in a timely manner. |
The Motley Fool
December 29, 2008
Brian Orelli |
Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes. |
The Motley Fool
December 19, 2008
Brian Orelli |
Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation. |
The Motley Fool
December 19, 2008
Brian Orelli |
Eli Lilly's Good News Misses the Mark EU approval of its blood thinner is nice, but U.S. approval is what will really matter. |
The Motley Fool
December 18, 2008
Brian Orelli |
A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis. |
The Motley Fool
December 18, 2008
Brian Orelli |
Pfizer Needs Bigger Deals Buy something significant already! |
The Motley Fool
December 18, 2008
Selena Maranjian |
Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009. |
The Motley Fool
December 18, 2008
Jim Gillies |
Best Stock for 2009: Somanetics Somanetics is a small medical-device maker with potential for 2009. |
| <Older 5331-5340 Newer> Return to current articles. |
